Merck Announces Virtual 2020 Annual Shareholders Meeting
May 08 2020 - 5:45AM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, announced today that in the interest of the health and
safety of its shareholders, directors, officers, employees and
meeting attendees in light of the current COVID-19 pandemic and the
declared state of emergency in New Jersey, the format of its 2020
Annual Meeting of Shareholders has been changed to a virtual
meeting. Merck’s 2020 Annual Meeting will be held on Tuesday, May
26, 2020 at 9:00 a.m. EDT, as previously announced.
Shareholders will not be able to attend the 2020 Annual Meeting
in person; however, shareholders of record at the close of business
on March 27, 2020 will be able to participate in the virtual 2020
Annual Meeting, vote their shares and ask questions through an
online meeting platform.
To participate in the virtual Annual Meeting, shareholders
should visit www.virtualshareholdermeeting.com/MRK2020 and enter
the 16-digit control number found on their proxy cards, voting
instruction forms or notices that accompanied their proxy
materials. Guests may also access the virtual Annual Meeting but in
listen-only mode. No control number is required for guests.
Additional information for shareholders on how to
participate:
- Access the meeting platform at
www.virtualshareholdermeeting.com/MRK2020 and enter your 16-digit
control number beginning at 8:45 a.m. EDT on Tuesday, May 26, 2020
to vote and submit a question during the meeting.
- To submit a question before the meeting, visit
www.proxyvote.com with your 16-digit control number and select the
“Submit a Question for Management” option.
- Merck will provide direct information to shareholder proponents
on how they can present their shareholder proposals during the
Annual Meeting.
- If you encounter any technical difficulties with the meeting
platform on the date of the Annual Meeting, technical support will
be available during this time and will remain available until the
virtual Annual Meeting has ended.
- Whether or not you plan to attend Merck's 2020 Annual Meeting,
we urge you to vote and submit your proxy in advance by one of the
methods described in the proxy materials for the 2020 Annual
Meeting.
About Merck For more than 125 years, Merck, known as MSD
outside of the United States and Canada, has been inventing for
life, bringing forward medicines and vaccines for many of the
world’s most challenging diseases in pursuit of our mission to save
and improve lives. We demonstrate our commitment to patients and
population health by increasing access to health care through
far-reaching policies, programs and partnerships. Today, Merck
continues to be at the forefront of research to prevent and treat
diseases that threaten people and animals – including cancer,
infectious diseases such as HIV and Ebola, and emerging animal
diseases – as we aspire to be the premier research-intensive
biopharmaceutical company in the world. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, Instagram,
YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA This news release of Merck & Co.,
Inc., Kenilworth, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200508005215/en/
Media: Pamela Eisele (267) 305-3558
Investors: Peter Dannenbaum (908) 740-1037
Michael DeCarbo (908) 740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024